www.taro.com

Trademarks and Copyright© The images and information contained in the Site are, to the fullest extent possible, copyrighted and otherwise proprietary. It is the policy of Taro to enforce its intellectual property rights to the fullest extent of the law, including (where applicable) seeking criminal sanctions.

Earnings Release

Receive E-mail AlertsE-mail Alert Icon Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign-up Now!

Earnings Press Releases

Date Title
Toggle Summary Taro Provides Results for December 31, 2023
Toggle Summary Taro Provides Results for September 30, 2023
Toggle Summary Taro Provides Results for the Quarter Ended June 30, 2023
Toggle Summary Taro Provides Results for Year Ended March 31, 2023
May 23, 2023 07:00 PM Eastern Daylight Time HAWTHORNE, N.Y.--( BUSINESS WIRE )--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2023. Quarter ended March 31, 2023* Highlights ─ compared to
Toggle Summary Taro Provides Results for December 31, 2022
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Jan. 24, 2023-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2022 . Quarter ended December 31, 2022 * Highlights ─ compared to December 31,
Toggle Summary Taro Provides Results for September 30, 2022
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Oct. 27, 2022-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2022 . Quarter ended September 30, 2022 * Highlights ─ compared to September
Terms of Use		 |
Privacy Statement		 |
Safe Harbor Statement